Oculis Pharmaceuticals
Oculis Pharmaceuticals4
About
What does Oculis Pharmaceuticals do?
Oculis is a global biopharmaceutical company (Nasdaq: OCS) focused on developing treatments for ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. The company's proprietary OPTIREACH® formulation technology enables eye drops to effectively reach the back of the eye. Its late-stage clinical pipeline includes Privosegtor (FDA Breakthrough Therapy Designation for optic neuritis), OCS-01 in pivotal studies for diabetic macular edema, and Licaminlimab for dry eye disease…
Where is Oculis Pharmaceuticals headquartered?
Oculis Pharmaceuticals is headquartered in Zug, Switzerland.
When was Oculis Pharmaceuticals founded?
Oculis Pharmaceuticals was founded in 2017.
What industry does Oculis Pharmaceuticals operate in?
Oculis Pharmaceuticals operates in Biotechnology, Pharmaceuticals, Ophthalmology, Drug Development, HealthTech, Biopharmaceuticals.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.